Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.
Ajai Chari, MD
Advertisement
Articles by Ajai Chari, MD
Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.
Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Dr Chari on the FDA Approval of Talquetamab in Relapsed/Refractory Multiple MyelomaPublished: August 14th 2023 | Updated:
Study Overview: COLUMBA and PLEIADESPublished: May 13th 2020 | Updated:
Infusion-Related Adverse EventsPublished: May 13th 2020 | Updated:
Medication Supplements Prior to IV AdministrationPublished: May 13th 2020 | Updated:
Community Advice: SQ Formulation of DaratumumabPublished: May 13th 2020 | Updated:
Real-World Experience With SQ Monoclonal AntibodiesPublished: May 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5